截至9月30日，春立医疗股东户数6164.00，较上期增加4.12%；人均流通股46906股，较上期减少 3.95%。2025年1月-9月，春立医疗实现营业收入7.56亿元，同比增长48.75%；归母净利润1.92亿元，同 比增长213.21%。 分红方面，春立医疗A股上市后累计派现3.59亿元。近三年，累计派现3.09亿元。 机构持仓方面，截止2025年9月30日，春立医疗十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股295.85万股，为新进股东。中欧景气精选混合A（020876）位居第五大流通股东，持股 283.26万股，为新进股东。平安低碳经济混合A（009878）位居第八大流通股东，持股210.00万股，相 比上期减少167.00万股。南方医药保健灵活配置混合A（000452）退出十大流通股东之列。 春立医疗今年以来股价涨95.67%，近5个交易日跌3.14%，近20日跌3.11%，近60日涨10.45%。 资料显示，北京市春立正达医疗器械股份有限公司位于北京市通州区通州经济开发区南区鑫觅西二路10 号，成立日期1998年2月12日，上市日期2021年12月30日，公司主营业务涉及北京 ...

Core Viewpoint - The stock price of Jianzhijia has shown a slight increase of 2.04% on November 26, 2023, with a current price of 20.52 CNY per share, despite a year-to-date decline of 6.79% [1] Company Overview - Jianzhijia Pharmaceutical Chain Group Co., Ltd. is located in Kunming, Yunnan Province, and was established on September 27, 2004. The company was listed on December 1, 2020. Its main business involves the retail of health products, including pharmaceuticals, health foods, personal care products, and daily consumables [1] - The revenue composition of Jianzhijia includes: prescription and non-prescription drugs (72.60%), with non-prescription drugs at 39.64% and prescription drugs at 32.96%. Other segments include medical devices (7.44%), other (5.52%), convenience products (5.05%), health foods (4.84%), traditional Chinese medicine (3.28%), personal care products (1.18%), and health check services (0.09%) [1] Financial Performance - For the period from January to September 2025, Jianzhijia reported a revenue of 6.549 billion CNY, a year-on-year decrease of 2.77%. The net profit attributable to the parent company was 101 million CNY, reflecting a slight decrease of 0.22% year-on-year [2] - Since its A-share listing, Jianzhijia has distributed a total of 715 million CNY in dividends, with 473 million CNY distributed over the past three years [3] Shareholder Information - As of September 30, 2025, Jianzhijia had 15,100 shareholders, a slight decrease of 0.04% from the previous period. The average circulating shares per person increased by 0.04% to 10,240 shares [2] - Among the top ten circulating shareholders, Rongtong Health Industry Flexible Allocation Mixed A/B holds 7.1 million shares, remaining unchanged from the previous period. Meanwhile, Guangfa Innovation Upgrade Mixed has exited the top ten list [3]

Core Viewpoint - Shandong Steel's stock has shown fluctuations with a recent increase of 2.04%, while the company has experienced a decline in revenue but a significant increase in net profit year-on-year [1][2]. Group 1: Stock Performance - As of November 26, Shandong Steel's stock price is 1.50 CNY per share, with a market capitalization of 16.048 billion CNY [1]. - The stock has increased by 3.45% year-to-date, but has seen declines of 3.23% over the last five trading days, 6.83% over the last 20 days, and 4.46% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Shandong Steel reported operating revenue of 54.828 billion CNY, a decrease of 14.77% year-on-year [2]. - The company achieved a net profit attributable to shareholders of 140 million CNY, reflecting a year-on-year increase of 109.64% [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders is 199,000, a decrease of 3.98% from the previous period [2]. - The average number of circulating shares per shareholder is 53,767, an increase of 4.14% [2]. - The company has distributed a total of 3.474 billion CNY in dividends since its A-share listing, with 321 million CNY distributed in the last three years [3]. Group 4: Major Shareholders - As of September 30, 2025, Hong Kong Central Clearing Limited is the fourth-largest circulating shareholder, holding 98.304 million shares, an increase of 58.581 million shares from the previous period [3]. - Guotai CSI Steel ETF is the fifth-largest circulating shareholder, holding 53.728 million shares as a new shareholder [3].

Core Viewpoint - The stock of Kexing Pharmaceutical has shown significant fluctuations, with a year-to-date increase of 57.84% and a recent decline over the past 20 and 60 days, indicating volatility in its market performance [1]. Financial Performance - For the period from January to September 2025, Kexing Pharmaceutical achieved a revenue of 1.148 billion yuan, representing a year-on-year growth of 10.54% [2]. - The net profit attributable to shareholders for the same period was 111 million yuan, reflecting a substantial year-on-year increase of 547.70% [2]. Shareholder and Market Activity - As of September 30, 2025, the number of shareholders for Kexing Pharmaceutical increased by 25.03% to 11,800, while the average circulating shares per person decreased by 19.37% to 17,102 shares [2]. - The stock has appeared on the "龙虎榜" (a list of stocks with significant trading activity) six times this year, with the most recent appearance on July 3 [1]. Dividend Distribution - Since its A-share listing, Kexing Pharmaceutical has distributed a total of 51.5446 million yuan in dividends, with 15.7785 million yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, notable changes in institutional holdings include a decrease in shares held by the second-largest shareholder, E Fund Medical Care Industry Mixed A, by 1.6069 million shares, while the fifth-largest shareholder, Fortune Tianhui Growth Mixed A/B, increased its holdings by 10,000 shares [3].

Core Viewpoint - The stock of Visionox Technology Co., Ltd. has shown fluctuations, with a recent increase of 2.02% to 9.11 CNY per share, while the company has experienced a year-to-date decline of 11.38% [1] Financial Performance - For the period from January to September 2025, Visionox reported a revenue of 6.051 billion CNY, reflecting a year-on-year growth of 3.50%. However, the net profit attributable to shareholders was -1.623 billion CNY, which is an increase of 9.67% compared to the previous year [2] Shareholder Information - As of November 20, 2025, the number of shareholders for Visionox increased to 71,700, marking a rise of 14.69%. The average circulating shares per person decreased by 12.81% to 19,444 shares [2] Dividend Distribution - Since its A-share listing, Visionox has distributed a total of 53.2384 million CNY in dividends, with no dividends paid in the last three years [3] Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited was the eighth largest circulating shareholder of Visionox, holding 11.0486 million shares, which is an increase of 2.8175 million shares from the previous period [3]

11月26日，奥浦迈盘中上涨2.03%，截至09:49，报56.68元/股，成交354.27万元，换手率0.06%，总市值 64.51亿元。 奥浦迈今年以来股价涨57.23%，近5个交易日跌1.72%，近20日跌8.74%，近60日涨0.91%。 资料显示，上海奥浦迈生物科技股份有限公司位于上海市浦东新区紫萍路908弄28号楼，成立日期2013 年11月27日，上市日期2022年9月2日，公司主营业务涉及从事细胞培养产品与服务。主营业务收入构成 为：产品87.34%，服务12.53%，其他0.13%。 机构持仓方面，截止2025年9月30日，奥浦迈十大流通股东中，中欧医疗健康混合A（003095）位居第 六大流通股东，持股400.86万股，相比上期增加252.62万股。工银前沿医疗股票A（001717）位居第七 大流通股东，持股330.01万股，相比上期增加40.00万股。中欧医疗创新股票A（006228）位居第九大流 通股东，持股265.16万股，为新进股东。招商医药健康产业股票（000960）退出十大流通股东之列。 责任编辑：小浪快报 奥浦迈所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包 ...

Group 1 - A total of 1859 share repurchase plans have been implemented this year, involving 1365 companies, with 365 companies completing repurchases exceeding 100 million yuan [1] - The total repurchase amount for the year is approximately 227.5 billion yuan, signaling a positive market sentiment from listed companies [1] - In November, 35 listed companies announced repurchase plans, including Kweichow Moutai planning to repurchase shares worth 1.5 to 3 billion yuan [3] Group 2 - Midea Group has updated its repurchase progress, with 1.51 billion yuan completed out of a planned 1.5 to 3 billion yuan repurchase, and 8.065 billion yuan out of a 5 to 10 billion yuan plan [8] - Other companies like GoerTek and BOE Technology have also made significant progress in their repurchase plans, with GoerTek completing 9.4 billion yuan and BOE 704 million yuan [8] - The trend of share repurchases and increases by shareholders is seen as crucial for the long-term healthy development of the capital market, improving investor sentiment and stabilizing market expectations [8]

Core Viewpoint - New Feng Ming's stock has shown significant performance with a year-to-date increase of 54.73%, despite a recent decline of 2.31% over the last five trading days [1] Group 1: Stock Performance - As of November 25, New Feng Ming's stock price is 16.88 CNY per share, with a market capitalization of 25.734 billion CNY [1] - The stock has experienced a trading volume of 92.16 million CNY and a turnover rate of 0.37% [1] - The stock has seen a 5.43% increase over the last 20 days and a 15.46% increase over the last 60 days [1] Group 2: Financial Performance - For the period of January to September 2025, New Feng Ming reported a revenue of 51.542 billion CNY, reflecting a year-on-year growth of 4.77% [2] - The net profit attributable to shareholders for the same period was 0.869 billion CNY, marking a year-on-year increase of 16.53% [2] Group 3: Shareholder Information - As of October 20, 2025, the number of shareholders for New Feng Ming is 20,400, a decrease of 0.76% from the previous period [2] - The average number of circulating shares per shareholder is 74,455, which has increased by 1.02% [2] - New Feng Ming has distributed a total of 1.733 billion CNY in dividends since its A-share listing, with 720 million CNY distributed in the last three years [3]

Core Points - The stock price of New Zhonggang increased by 2.02% on November 25, reaching 9.08 CNY per share, with a total market capitalization of 3.637 billion CNY [1] - Year-to-date, New Zhonggang's stock price has risen by 37.37%, but it has experienced a decline of 3.61% over the last five trading days [2] - The company has been listed on the "Dragon and Tiger List" nine times this year, with the most recent instance on July 17, where it recorded a net buy of -51.2672 million CNY [2] Company Overview - New Zhonggang, established on October 17, 1997, is located in Shengzhou City, Zhejiang Province, and was listed on July 7, 2021 [2] - The company's main business involves the production and supply of thermal and electric products through cogeneration, with revenue composition being 95.17% from cogeneration, 4.73% from energy storage, and 0.10% from other sources [2] - As of September 30, the number of shareholders increased by 12.16% to 22,900, while the average circulating shares per person decreased by 10.83% to 17,497 shares [2] Financial Performance - For the period from January to September 2025, New Zhonggang reported operating revenue of 529 million CNY, a year-on-year decrease of 18.48%, while the net profit attributable to the parent company was 91.8345 million CNY, reflecting a year-on-year increase of 2.51% [2] - Since its A-share listing, the company has distributed a total of 344 million CNY in dividends, with 204 million CNY distributed over the past three years [3]

Core Viewpoint - HeSteel Resources' stock price has shown a year-to-date increase of 32.46%, despite a slight decline in the recent trading periods [2] Financial Performance - For the period from January to September 2025, HeSteel Resources reported a revenue of 4.303 billion yuan, representing a year-on-year decrease of 7.47% [2] - The net profit attributable to shareholders for the same period was 538 million yuan, down 6.91% year-on-year [2] Stock Market Activity - As of November 25, HeSteel Resources' stock price was 17.75 yuan per share, with a market capitalization of 11.586 billion yuan [1] - The stock experienced a trading volume of 58.4435 million yuan and a turnover rate of 0.53% [1] - The stock has seen a net inflow of main funds amounting to 6.6941 million yuan, with significant buying activity from large orders [1] Shareholder Information - As of September 30, 2025, the number of shareholders for HeSteel Resources was 28,300, a decrease of 6.54% from the previous period [2] - The average number of circulating shares per shareholder increased by 7.00% to 22,171 shares [2] Dividend Distribution - HeSteel Resources has cumulatively distributed dividends amounting to 1.298 billion yuan since its A-share listing, with 914 million yuan distributed over the past three years [3] Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited was the fourth largest circulating shareholder, holding 11.362 million shares, an increase of 1.7024 million shares from the previous period [3] - HSBC Jintrust Small Cap Stock was the eighth largest circulating shareholder, holding 6.5423 million shares, up by 171,050 shares [3] - Guotai CSI Steel ETF was a new entrant among the top ten circulating shareholders, holding 4.6 million shares [3]